271 related articles for article (PubMed ID: 19609735)
1. Survey of the enthesopathy of X-linked hypophosphatemia and its characterization in Hyp mice.
Liang G; Katz LD; Insogna KL; Carpenter TO; Macica CM
Calcif Tissue Int; 2009 Sep; 85(3):235-46. PubMed ID: 19609735
[TBL] [Abstract][Full Text] [Related]
2. Mineral tessellation in mouse enthesis fibrocartilage, Achilles tendon, and Hyp calcifying enthesopathy: A shared 3D mineralization pattern.
Buss DJ; Rechav K; Reznikov N; McKee MD
Bone; 2023 Sep; 174():116818. PubMed ID: 37295663
[TBL] [Abstract][Full Text] [Related]
3. Mineralizing enthesopathy is a common feature of renal phosphate-wasting disorders attributed to FGF23 and is exacerbated by standard therapy in hyp mice.
Karaplis AC; Bai X; Falet JP; Macica CM
Endocrinology; 2012 Dec; 153(12):5906-17. PubMed ID: 23038738
[TBL] [Abstract][Full Text] [Related]
4. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice.
Liu S; Tang W; Zhou J; Vierthaler L; Quarles LD
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1636-44. PubMed ID: 17848631
[TBL] [Abstract][Full Text] [Related]
5. Hexa-D-arginine treatment increases 7B2•PC2 activity in hyp-mouse osteoblasts and rescues the HYP phenotype.
Yuan B; Feng JQ; Bowman S; Liu Y; Blank RD; Lindberg I; Drezner MK
J Bone Miner Res; 2013 Jan; 28(1):56-72. PubMed ID: 22886699
[TBL] [Abstract][Full Text] [Related]
6. Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia.
Yuan B; Takaiwa M; Clemens TL; Feng JQ; Kumar R; Rowe PS; Xie Y; Drezner MK
J Clin Invest; 2008 Feb; 118(2):722-34. PubMed ID: 18172553
[TBL] [Abstract][Full Text] [Related]
7. The Enthesopathy of XLH Is a Mechanical Adaptation to Osteomalacia: Biomechanical Evidence from Hyp Mice.
Macica CM; Luo J; Tommasini SM
Calcif Tissue Int; 2022 Sep; 111(3):313-322. PubMed ID: 35618776
[TBL] [Abstract][Full Text] [Related]
8. Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice.
Aono Y; Hasegawa H; Yamazaki Y; Shimada T; Fujita T; Yamashita T; Fukumoto S
J Bone Miner Res; 2011 Apr; 26(4):803-10. PubMed ID: 20939065
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of the DMP1 C-terminal fragment stimulates FGF23 and exacerbates the hypophosphatemic rickets phenotype in Hyp mice.
Martin A; David V; Li H; Dai B; Feng JQ; Quarles LD
Mol Endocrinol; 2012 Nov; 26(11):1883-95. PubMed ID: 22930691
[TBL] [Abstract][Full Text] [Related]
10. Impaired 1,25-dihydroxyvitamin D3 action underlies enthesopathy development in the Hyp mouse model of X-linked hypophosphatemia.
Rana R; Baker JT; Sorsby M; Jagga S; Venkat S; Almardini S; Liu ES
JCI Insight; 2023 Sep; 8(17):. PubMed ID: 37490334
[TBL] [Abstract][Full Text] [Related]
11. Molecular analysis of enthesopathy in a mouse model of hypophosphatemic rickets.
Liu ES; Martins JS; Zhang W; Demay MB
Development; 2018 Aug; 145(15):. PubMed ID: 30002128
[TBL] [Abstract][Full Text] [Related]
12. FGF23-induced hypophosphatemia persists in Hyp mice deficient in the WNT coreceptor Lrp6.
Uchihashi K; Nakatani T; Goetz R; Mohammadi M; He X; Razzaque MS
Contrib Nephrol; 2013; 180():124-37. PubMed ID: 23652555
[TBL] [Abstract][Full Text] [Related]
13. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice.
Sitara D; Razzaque MS; Hesse M; Yoganathan S; Taguchi T; Erben RG; Jüppner H; Lanske B
Matrix Biol; 2004 Nov; 23(7):421-32. PubMed ID: 15579309
[TBL] [Abstract][Full Text] [Related]
14. Contribution of imaging to the diagnosis and follow up of X-linked hypophosphatemia.
Adamsbaum C; Laredo JD; Briot K; Linglart A
Arch Pediatr; 2021 Oct; 28(7):594-598. PubMed ID: 34583869
[TBL] [Abstract][Full Text] [Related]
15. Sclerostin antibody improves phosphate metabolism hormones, bone formation rates, and bone mass in adult Hyp mice.
Carpenter KA; Davison R; Shakthivel S; Anderson KD; Ko FC; Ross RD
Bone; 2022 Jan; 154():116201. PubMed ID: 34537437
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of human PHEX under the human beta-actin promoter does not fully rescue the Hyp mouse phenotype.
Erben RG; Mayer D; Weber K; Jonsson K; Jüppner H; Lanske B
J Bone Miner Res; 2005 Jul; 20(7):1149-60. PubMed ID: 15940367
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of Phex in osteoblasts fails to rescue the Hyp mouse phenotype.
Liu S; Guo R; Tu Q; Quarles LD
J Biol Chem; 2002 Feb; 277(5):3686-97. PubMed ID: 11713245
[TBL] [Abstract][Full Text] [Related]
18. Tissue-specific mineralization defects in the periodontium of the Hyp mouse model of X-linked hypophosphatemia.
Coyac BR; Falgayrac G; Baroukh B; Slimani L; Sadoine J; Penel G; Biosse-Duplan M; Schinke T; Linglart A; McKee MD; Chaussain C; Bardet C
Bone; 2017 Oct; 103():334-346. PubMed ID: 28764922
[TBL] [Abstract][Full Text] [Related]
19. Excessive Osteocytic Fgf23 Secretion Contributes to Pyrophosphate Accumulation and Mineralization Defect in Hyp Mice.
Murali SK; Andrukhova O; Clinkenbeard EL; White KE; Erben RG
PLoS Biol; 2016 Apr; 14(4):e1002427. PubMed ID: 27035636
[TBL] [Abstract][Full Text] [Related]
20. Dentoalveolar Defects in the
Zhang H; Chavez MB; Kolli TN; Tan MH; Fong H; Chu EY; Li Y; Ren X; Watanabe K; Kim DG; Foster BL
J Dent Res; 2020 Apr; 99(4):419-428. PubMed ID: 31977267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
